The trial involved adults and adolescents aged 12 years and above with MOGAD, offering an open-label extension.
The era of off-label guesswork for patients living with the rare autoimmune disorder MOGAD may soon be over, as a phase 3 ...
Satralizumab significantly reduces relapse risk in patients with relapsing MOGAD, according to phase 3 METEOROID trial results presented at AAN 2026.
Satralizumab reduced relapse risk by 68% in the phase III METEOROID trial for myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), marking the first successful randomized ...
Treatment with satralizumab reduced the risk of new MOGAD relapse by 68% vs placebo. Positive results were announced from a phase 3 trial evaluating satralizumab for the treatment of myelin ...
Hosted on MSN
First clinical trial in MOGAD meets primary endpoint
The interleukin-6 (IL-6) inhibitor satralizumab (Enspryng) met its primary endpoint in the phase III METEOROID trial of ...
Add Yahoo as a preferred source to see more of our stories on Google. Have you ever looked up at a “shooting star” and wondered what you’re actually seeing? The terms meteor, meteorite, and meteoroid ...
Meteoroid impacts represent one of the most dynamic interactions between extraterrestrial bodies and the Earth’s atmosphere. When meteoroids enter the atmosphere, they experience rapid deceleration ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results